Report Code: A13330 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Bile duct cancer, also known as cholangiocarcinoma, is a rare disease wherein malignant cancer cells form from the bile duct. Bile duct forms off a network of different tubes that connects liver, small intestine, and the gall bladder. The smallest ducts combine to form hepatic duct, which eventually leads to liver. The bile passes from liver, then through the hepatic duct, and finally reaches the gall bladder. There are 2 types of bile duct cancer, intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic cancer, are also known as intrahepatic cholangiocarcinoma, are formed inside the liver, whereas it is vice versa in case of extrahepatic bile duct cancer. Furthermore, extrahepatic bile duct cancer is made up of hilum and distal regions. Few of the risk factors associated with bile duct cancer, which increase the chances of occurrence of cancer include primary sclerosing cholangitis, chronic ulcerative colitis, and bile duct cysts. Furthermore, few of the frequent symptoms and side effects associated with bile duct cancer include jaundice, hay fever, clay colored stool, and fever. Diagnosis is carried out through a slumber, including carcinogenic embryonic & CA 19-9 tumor marker test, magnetic resonance imaging (MRI), and ultrasound. Additionally, biopsy procedures such as laparoscopy and endoscopic retrograde cholangiopancreatography can be employed for obtaining a tissue sample to diagnose bile duct cancer in the patient.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the bile duct cancer drug market.
Top Impacting Factors
Key Market Trends
Key Benefits of the Report
Questions Answered in the Bile Duct Cancer Drug Report
Bile Duct Cancer Drug Market Report Highlights
Aspects | Details |
---|---|
By Product |
|
By Distribution Channel |
|
By Application |
|
By Region |
|
Key Market Players | Accord Healthcare Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Eli Lilly and Company, F. Hoffman-La Roche AG, Novartis AG, Kyowa Hakko Kirin Co Ltd., Teva Pharmaceuticals Industries Ltd., Intercept Pharmaceuticals, Inc., Celgene Corporation, Sanofi, Fresenius Kabi AG, Johnson and Johnson, Mylan N.V., Delcath Systems Inc. |
Loading Table Of Content...
Start reading.
This Report and over 71,295+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers